Pharmacogenomic Determinants of Interindividual Drug Response Variability: From Discovery to Implementation
- PMID: 33801919
- PMCID: PMC7999913
- DOI: 10.3390/genes12030393
Pharmacogenomic Determinants of Interindividual Drug Response Variability: From Discovery to Implementation
Abstract
Since the term "pharmacogenetics" was first published in the late 1950s by Friedrich Vogel, the field has evolved into genome-wide association studies identifying novel variants associated with drug response phenotypes, international societies and consortia dedicated to pharmacogenomic research and clinical implementation, clinical practice guidelines, and the increasing availability of pharmacogenomic tests for healthcare providers in both hospital and primary care [...].
Conflict of interest statement
S.A.S. is a paid consultant of Sema4.
Similar articles
-
The challenges of implementing pharmacogenomic testing in the clinic.Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):567-577. doi: 10.1080/14737167.2017.1385395. Epub 2017 Oct 3. Expert Rev Pharmacoecon Outcomes Res. 2017. PMID: 28949250 Review.
-
The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen.Pharmacogenomics. 2017 Jul;18(11):1041-1045. doi: 10.2217/pgs-2017-0093. Epub 2017 Jul 7. Pharmacogenomics. 2017. PMID: 28685652 No abstract available.
-
Individualizing pharmacogenomic test results in the context of the microbiome.Per Med. 2020 Nov;17(6):459-468. doi: 10.2217/pme-2020-0077. Epub 2020 Oct 7. Per Med. 2020. PMID: 33026284 Review.
-
Characterizing Pharmacogenomic-Guided Medication Use With a Clinical Data Repository.Clin Pharmacol Ther. 2017 Aug;102(2):340-348. doi: 10.1002/cpt.611. Epub 2017 Jun 5. Clin Pharmacol Ther. 2017. PMID: 28073152 Free PMC article.
-
Implementation of wide-scale pharmacogenetic testing in primary care.Pharmacogenomics. 2019 Aug;20(12):903-913. doi: 10.2217/pgs-2019-0043. Pharmacogenomics. 2019. PMID: 31453774
Cited by
-
Impact and Enablers of Pharmacogenetic-Informed Treatment Decisions-A Longitudinal Mixed-Methods Study Exploring the Patient Perspective.Pharmacy (Basel). 2025 Jan 31;13(1):14. doi: 10.3390/pharmacy13010014. Pharmacy (Basel). 2025. PMID: 39998012 Free PMC article.
-
Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study.Pharmgenomics Pers Med. 2023 Jul 3;16:693-706. doi: 10.2147/PGPM.S415259. eCollection 2023. Pharmgenomics Pers Med. 2023. PMID: 37426898 Free PMC article.
References
-
- de Carvalho C.D., Pereira Colares Leitao L., Mello Junior F.A.R., Vieira Wanderley A., Souza T.P., de Sa B.A.R., Cohen-Paes A., Rodrigues Fernandes M., Santos S., Salim Khayat A., et al. Association between the TPMT*3C (rs1142345) Polymorphism and the Risk of Death in the Treatment of Acute Lymphoblastic Leukemia in Children from the Brazilian Amazon Region. Genes. 2020;11:1132. doi: 10.3390/genes11101132. - DOI - PMC - PubMed
-
- Kodidela S., Dorababu P., Thakkar D.N., Dubashi B., Sundaram R., Muralidharan N., Nidanapu R.P., Aribandi A., Pradhan S.C., Uppugunduri C.R.S. Association of NUDT15*3 and FPGS 2572C>T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy in Indian Patients with Acute Lymphoblastic Leukemia. Genes. 2020;11:594. doi: 10.3390/genes11060594. - DOI - PMC - PubMed
-
- Bergmeijer T.O., Yasmina A., Vos G.J.A., Janssen P.W.A., Hackeng C.M., Kelder J.C., Verma S.S., Ritchie M.D., Gong L., Klein T.E., et al. Effect of CYP3A4*22 and PPAR-alpha Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. Genes. 2020;11:1068. doi: 10.3390/genes11091068. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical